Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02915237 · ClinicalTrials.gov registry record · Phase 1

Development of a Polyphenol-rich Dietary Preparation for Treating Veterans With Gulf War Illness

A Phase 1 study, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
Phase 1
Development phase
36
Enrollment target

NCT02915237 is a Phase 1 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 36 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02915237, a Phase 1 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
Phase 1
Development phase
36 participants
Enrollment target

Study Summary

Gulf War Illness (GWI) is a multi-symptom disorder that is characterized by complex traits such as fatigue, headaches, joint pain, insomnia, and memory problems. With no treatment for GWI currently available, there is an urgent need to develop novel interventions to alleviate major GWI clinical complications. Recent evidence highlights the potential value of flavonoids, a subclass of organic chemical called polyphenols abundantly found in some plants and common dietary preparations, in helping relieve clinical complications in Veterans with GWI. The overall goal is to test whether daily consumption of commercially available Concord grape juice, which is very Flavonoid-rich, is effective for treating cognitive deficits and chronic fatigue in Veterans with GWI.

Interventions

  • DIETARY_SUPPLEMENT Concord grape juice
  • DIETARY_SUPPLEMENT Placebo Beverage

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2016-08
Est. Completion 2019-01-17
Phase Phase 1

What the Registry Record Tells You About NCT02915237

The ClinicalTrials.gov registry entry for NCT02915237 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Concord grape juice is the first listed.

NCT02915237 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02915237 about?

NCT02915237 is a clinical study titled "Development of a Polyphenol-rich Dietary Preparation for Treating Veterans With Gulf War Illness". Gulf War Illness (GWI) is a multi-symptom disorder that is characterized by complex traits such as fatigue, headaches, joint pain, insomnia, and memory problems. With no treatment for GWI currently available, there is an urgent need to develop novel interventions to alleviate major GWI clinical comp...

What is the current status of trial NCT02915237?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2016-08. Estimated completion is 2019-01-17.

What interventions are being tested in trial NCT02915237?

The interventions under investigation include: Concord grape juice (DIETARY_SUPPLEMENT), Placebo Beverage (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT02915237?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.